Print Email
 

Bottom Line Summary

Risk of Breast Cancer after Stopping Combination Hormonal Therapy


The Risk of Invasive Breast Cancer Persists after Stopping Combination Hormonal Therapy

Results from the extension phase of the Women's Health Initiative Trials

Download PDF

The Bottom Line:

  • Women receiving combination hormone therapy with conjugated equine estrogen plus medroxyprogesterone acetate may have increased risk of invasive breast cancer which persists after stopping therapy, but have no increased risk of coronary heart disease.
  • Women without a uterus receiving conjugated equine estrogen alone have a lower risk of invasive breast cancer and no change in their risk for coronary heart disease during or after the intervention.
  • The increased risk of stroke seen in women in both the combination and estrogen alone groups during the intervention phase does not persist at the end of the cumulative follow-up period.

Tips for Discussion with Patients:

  • This is an extension study, results may have been affected by unmeasured variables.
  • Risk of invasive breast cancer persists over time for combination therapy with estrogen and progesterone.
  • Participants in this study received conjugated equine estrogen 0.625 mg/day and medroxyprogesterone acetate 2.5 mg/day. Therefore, the results are applicable to these specific products at these specific doses. This study did not consider lower dose hormone therapy options or estrogen products other than conjugated equine estrogen.

References:

1. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2013; 310(13):1353-1368

Written by the Evidence-Based Medicine Task Force

  1. M.E. Beth Smith, DO
  2. KoKo Aung, MD, MPH
  3. Zackary Berger, MD, PhD
  4. Rebecca Beyth, MD, MSc
  5. Daniel Elliott, MD, MSCE
  6. Scott Kaatz, DO, MSc
  7. Deborah Korenstein, MD
  8. Jeremy Sussman, MD, MSc
  9. Daniella Zipkin, MD

 


 

Submit content to JGIM

JGIM encourages submission of articles aimed at improving patient care, education, and research in primary care and general internal medicine in all settings. Submissions must be original and not currently under consideration for publication in another peer- reviewed medium (paper or electronic).

Learn How to Submit Here

 

FEATURED ARTICLE

 

Darlyn Victor, MD, Paul Moots, MD and Jacqueline Fischer, MD

October 13, 2016

A 39-year-old African-A....

Read Article
 

Most Viewed Articles

73 Views

The Role of Community-Based Participatory Research to Inform Local Health Policy: A Case Study.

O’Brien, Matthew J.; Whitaker, Robert C.

Read Article| Download PDF
25 Views

The Role of Community-Based Participatory Research to Inform Local Health Policy: A Case Study.

O’Brien, Matthew J.; Whitaker, Robert C.

Read Article| Download PDF
31 Views

The Role of Community-Based Participatory Research to Inform Local Health Policy: A Case Study.

O’Brien, Matthew J.; Whitaker, Robert C.

Read Article| Download PDF

Most Recent Web Only Content

January

17

On the Penetrating Capacity of Ultrasound

Sarah Bugg

Read Article

December

20

Painful Eruption in a Mountain Biker

Jasna Ikanovic, MD and Animita Saha, MD

Read Article

November

19

Adverse Events In US Hospitals:1 in 3 Admissions Has At Least One Adverse Event

SGIM Evidence-Based Medicine Task Force

Read Article

August

25

Diagnostic Schema

Denise M. Connor, Rabih Geha, Mark Henderson, Jeff Kohlwes

Read Article